Valuation : Gilead Sciences, Inc.

Market Cap 181B 155B 146B 133B 249B 17,185B 250B 1,734B 670B 8,755B 678B 663B 27,736B P/E 2026 *
-44.5x
P/E 2027 * 18.2x
Enterprise Value 197B 170B 160B 146B 273B 18,778B 274B 1,895B 732B 9,567B 741B 725B 30,308B EV / Sales 2026 *
6.43x
EV / Sales 2027 * 5.81x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.33%
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+69.18%+57.76% - - 181B
+0.03%-3.09%+49.77%+91.69% 1,002B
-0.76%-2.95%+50.93%+66.34% 644B
+0.86%-4.13%+19.24%+68.37% 443B
-0.65%-2.92%+30.06%+36.31% 343B
+1.36%-13.84%+12.31%+28.12% 262B
-0.07%-4.01%-2.14%+11.02% 245B
-0.48%-11.65%+39.75%+50.82% 212B
-0.27%-4.31%-17.83%-57.81% 199B
-0.68%-2.65%+25.82%+91.64% 181B
Average +6.85%-5.00%+23.10%+42.95% 392.19B
Weighted average by Cap. +3.26%-4.24%+32.22%+57.58%

Financials

2026 *2027 *
Net sales 30.69B 26.41B 24.86B 22.66B 42.39B 2,920B 42.56B 295B 114B 1,488B 115B 113B 4,713B 32.68B 28.12B 26.48B 24.13B 45.14B 3,110B 45.32B 314B 121B 1,584B 123B 120B 5,019B
Net income -4.27B -3.68B -3.46B -3.16B -5.9B -407B -5.93B -41.05B -15.87B -207B -16.05B -15.7B -656B 10.28B 8.84B 8.33B 7.59B 14.19B 978B 14.25B 98.67B 38.13B 498B 38.58B 37.74B 1,578B
Net Debt 16.75B 14.41B 13.57B 12.36B 23.13B 1,593B 23.22B 161B 62.15B 812B 62.88B 61.51B 2,572B 9.12B 7.85B 7.39B 6.74B 12.6B 868B 12.65B 87.62B 33.86B 442B 34.26B 33.52B 1,401B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.65USD
Average target price
157.41USD
Spread / Average Target
+8.07%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!